Otsuka Partnership Brings $85M Upfront, 4DMT Raises $118M, Extends Cash Runway to H2 2028
FDMT has more than doubled off its 52-week low of $2.235.
Summary
4D Molecular Therapeutics announced a significant strategic partnership with Otsuka Pharmaceutical for its 4D-150 program in the Asia-Pacific region, securing an $85 million upfront payment and eligibility for up to $336 million in regulatory and commercial milestones. Concurrently, the company bolstered its financial position by raising $118 million through various equity financings, extending its cash runway into the second half of 2028. These financial developments, representing a substantial portion of the company's market capitalization, significantly de-risk its operations and provide capital for ongoing development. Furthermore, 4DMT reported positive clinical progress, including the completion of enrollment for the 4FRONT-1 Phase 3 trial for wet AMD and promising long-term interim data for both 4D-150 and 4D-710. Traders will be watching for the upcoming topline data from the 4FRONT-1 trial in H1 2027 and further clinical updates.
At the time of this announcement, FDMT was trading at $8.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $436.6M. The 52-week trading range was $2.24 to $12.34. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.